Donation

The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.

Order Print Edition

 

This publication discusses the use of Ninlaro (ixazomib)—a proteasome inhibitor—for the treatment of myeloma.
This publication discusses the use of Empliciti (elotuzumab)—a monoclonal antibody—for the treatment of myeloma.

Carvykti™ (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of adult…

This publication discusses the use of ABECMA® (idecabtagene vicleucel), the first CAR T-cell therapy to be approved by the FDA for patients with…
This publication covers monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

We Thank Our Sponsors:
BMS, GSK, Janssen, Karyopharm Therapeutics, Legend Biotech, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.